These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 3528213)
1. Influence of culture medium on susceptibility testing with BAY n 7133 and ketoconazole. Hoeprich PD; Merry JM J Clin Microbiol; 1986 Aug; 24(2):269-71. PubMed ID: 3528213 [TBL] [Abstract][Full Text] [Related]
2. In vitro antifungal activities of Bay n 7133 and Bay L 9139, two new orally absorbed antifungal imidazole derivatives, against pathogenic yeasts. Fromtling RA; Yu HP; Shadomy S Mycopathologia; 1984 Apr; 86(1):45-50. PubMed ID: 6330557 [TBL] [Abstract][Full Text] [Related]
3. Cryptococcus neoformans: comparisons of in vitro antifungal susceptibilities of serotypes AD and BC. Fromtling RA; Abruzzo GK; Bulmer GS Mycopathologia; 1986 Apr; 94(1):27-30. PubMed ID: 3014339 [TBL] [Abstract][Full Text] [Related]
4. Effect of medium composition on results of macrobroth dilution antifungal susceptibility testing of yeasts. Doern GV; Tubert TA; Chapin K; Rinaldi MG J Clin Microbiol; 1986 Oct; 24(4):507-11. PubMed ID: 3533974 [TBL] [Abstract][Full Text] [Related]
5. Antifungal susceptibility testing using the E test: comparison with the broth macrodilution technique. Chen SC; O'Donnell ML; Gordon S; Gilbert GL J Antimicrob Chemother; 1996 Feb; 37(2):265-73. PubMed ID: 8707736 [TBL] [Abstract][Full Text] [Related]
6. Fluconazole, itraconazole and ketoconazole in-vitro activity. A comparative study. Arzeni D; Barchiesi F; Ancarani F; Scalise G J Chemother; 1991 Jun; 3(3):139-42. PubMed ID: 1655990 [TBL] [Abstract][Full Text] [Related]
7. Comparison of a new commercial colorimetric microdilution method with a standard method for in-vitro susceptibility testing of Candida spp. and Cryptococcus neoformans. Davey KG; Szekely A; Johnson EM; Warnock DW J Antimicrob Chemother; 1998 Oct; 42(4):439-44. PubMed ID: 9818741 [TBL] [Abstract][Full Text] [Related]
8. Itraconazole vs amphotericin B: in vitro comparative evaluation of the minimal inhibitory concentration (MIC) against clinically isolated yeasts. Lombardi G; Gramegna G; Cavanna C; Poma G; Marangoni E; Michelone G Mycopathologia; 1989 Apr; 106(1):31-4. PubMed ID: 2549421 [TBL] [Abstract][Full Text] [Related]
9. In vitro susceptibilities of clinical yeast isolates to the new antifungal eberconazole compared with their susceptibilities to clotrimazole and ketoconazole. Torres-Rodríguez JM; Mendez R; López-Jodra O; Morera Y; Espasa M; Jimenez T; Lagunas C Antimicrob Agents Chemother; 1999 May; 43(5):1258-9. PubMed ID: 10223946 [TBL] [Abstract][Full Text] [Related]
10. In vitro susceptibility of 119 yeast isolates to fluconazole, 5-fluorocytosine, amphotericin B and ketoconazole. Morace G; Manzara S; Dettori G Chemotherapy; 1991; 37(1):23-31. PubMed ID: 2013239 [TBL] [Abstract][Full Text] [Related]
11. Multicenter comparison of the sensititre YeastOne Colorimetric Antifungal Panel with the National Committee for Clinical Laboratory standards M27-A reference method for testing clinical isolates of common and emerging Candida spp., Cryptococcus spp., and other yeasts and yeast-like organisms. Espinel-Ingroff A; Pfaller M; Messer SA; Knapp CC; Killian S; Norris HA; Ghannoum MA J Clin Microbiol; 1999 Mar; 37(3):591-5. PubMed ID: 9986817 [TBL] [Abstract][Full Text] [Related]
12. In-vitro studies with four new antifungal agents: BAY n 7133, bifonazole (BAY h 4502), ICI 153,066 and Ro 14-4767/002. Shadomy S; Espinel-Ingroff A; Kerkering TM Sabouraudia; 1984; 22(1):7-15. PubMed ID: 6322364 [TBL] [Abstract][Full Text] [Related]
13. In vitro antifungal activity of saperconazole (R 66905) against Candida and Torulopsis. Mallié M; Montès B; Lebecq JC; Bastide JM Mycoses; 1989 Dec; 32(12):631-7. PubMed ID: 2695841 [TBL] [Abstract][Full Text] [Related]
14. Antifungal susceptibility testing of yeast isolates from blood cultures by microbroth dilution and the E test. Simor AE; Goswell G; Louie L; Lee M; Louie M Eur J Clin Microbiol Infect Dis; 1997 Sep; 16(9):693-7. PubMed ID: 9352266 [TBL] [Abstract][Full Text] [Related]
15. In vitro studies of a new antifungal triazole, D0870, against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts. Peng T; Galgiani JN Antimicrob Agents Chemother; 1993 Oct; 37(10):2126-31. PubMed ID: 8257134 [TBL] [Abstract][Full Text] [Related]
16. The influence of antifungal antibiotics on some determinants of virulence in Candida albicans and Cryptococcus neoformans cells. Borowski J; Jakoniuk P; Jablońska W; Jakubicz W; Szpak A Experientia; 1974 Oct; 30(10):1210-1. PubMed ID: 4611784 [No Abstract] [Full Text] [Related]
17. Effect of culture media on the antifungal activity of miconazole and amphotericin B methyl ester. Hoeprich PD; Huston AC J Infect Dis; 1976 Oct; 134(4):336-41. PubMed ID: 789787 [TBL] [Abstract][Full Text] [Related]
18. [Antifungal susceptibility of yeasts by Etest. Comparison of 3 media]. Tapia C; León E; Palavecino E Rev Med Chil; 2003 Mar; 131(3):299-302. PubMed ID: 12790079 [TBL] [Abstract][Full Text] [Related]
19. Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program. Pfaller MA; Messer SA; Rhomberg PR; Castanheira M Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052853 [TBL] [Abstract][Full Text] [Related]
20. In vitro activities of two new antifungal azoles. Hoeprich PD; Merry JM Antimicrob Agents Chemother; 1984 Mar; 25(3):339-41. PubMed ID: 6721465 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]